Literature DB >> 3594071

Nifedipine effects in severe myocardial ischaemia in the dog due to left anterior descending coronary occlusion with left circumflex coronary artery constriction.

L Szekeres, E Udvary, A Végh.   

Abstract

The effects of nifedipine were studied in a model of local myocardial ischaemia, comprising anaesthetized thoracotomized dogs in which a critical constriction of the left circumflex coronary artery (LCX) was combined with sudden occlusion of the left anterior descending coronary artery (LAD). Since more than one coronary artery is involved in ischaemic heart disease, the model seems to reflect the clinical situation very closely. In this model, infusion of 1 microgram kg-1 min-1 nifedipine increased myocardial blood flow within the stenosed area served by the LCX as well as in the myocardial region supplied by the LAD, mainly in the subepicardium. Accordingly, the drug reduced ischaemic ST-segment elevation only in the epicardium. It is suggested that nifedipine directed flow to the sub-epicardium of the ischaemic area by improving the collateral circulation. This redistribution of flow resulted in a decrease in the endo/epicardial flow ratio. Nifedipine did not change the inhomogeneity of electrical activation indicating that it has no effect on the ischaemia-induced conduction delay. At the same time nifedipine was not able to reduce either the number of extrasystoles appearing in the early postocclusion and reperfusion phase or the incidence of ventricular fibrillation occurring mainly during reperfusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3594071      PMCID: PMC1853504          DOI: 10.1111/j.1476-5381.1987.tb08991.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Ca-blockers and peripheral circulation--physiological viewpoints.

Authors:  L G Ekelund
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  The pathophysiology of malignant ventricular arrhythmias during acute myocardial ischemia.

Authors:  D O Williams; B J Scherlag; R R Hope; N el-Sherif; R Lazzara
Journal:  Circulation       Date:  1974-12       Impact factor: 29.690

4.  Effect of nitrates and other coronary dilators on large and small coronary vessels: an hypothesis for the mechanism of action of nitrates.

Authors:  M M Winbury; B B Howe; M A Hefner
Journal:  J Pharmacol Exp Ther       Date:  1969-07       Impact factor: 4.030

5.  Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

Authors:  G Ellrodt; C Y Chew; B N Singh
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

6.  Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium.

Authors:  W G Nayler; R Ferrari; A Williams
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

7.  Importance of myocardial blood flow changes in the protective action of diltiazem in a new model of myocardial ischaemia.

Authors:  L Szekeres; E Udvary; A Végh
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

Review 8.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

9.  The effects of nifedipine on acute experimental myocardial ischemia and infarction in dogs.

Authors:  A P Selwyn; E Welman; K Fox; P Horlock; T Pratt; M Klein
Journal:  Circ Res       Date:  1979-01       Impact factor: 17.367

10.  Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.

Authors:  P D Henry; R Shuchleib; L J Borda; R Roberts; J R Williamson; B E Sobel
Journal:  Circ Res       Date:  1978-09       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.